CATEGORY: DIET & WEIGHT
Adults with type 2 diabetes who took a weekly injection of survodutide, an experimental drug that acts on two hormones at once, lost 9.8% of their body weight over 76 weeks. The placebo group lost 3.9%. Those figures count everyone who started the trial, including people who stopped their shots along the way, so they’re the conservative read of what the drug did.1 Survodutide isn’t approved anywhere yet. Its maker, Boehringer Ingelheim, funded the study, which was published in the New England Journal of Medicine.
One Shot, Two Hormone Signals
Most weight-loss injections in use today work through GLP-1, a gut hormone that quiets appetite and slows the stomach’s emptying. Survodutide adds a second signal: glucagon, a hormone made in the pancreas that tells the body to burn stored fuel. Think of it as easing off the gas pedal while also turning up the furnace. Whether that second signal earns its keep in people is exactly what trials like this one are built to find out.
What 76 Weeks of Blinded Injections Showed
Roughly 750 adults with type 2 diabetes and a body-mass index of at least 27 took part. A randomization system sorted them, one to one to one, into weekly survodutide at 3.6 milligrams, at 6.0 milligrams, or a look-alike placebo. Neither the participants nor their doctors knew who was getting what. The average participant was about 56 years old, with a body-mass index of 36.5.1 Counting everyone randomized, the lower dose trimmed weight by 8.2% and the higher dose by 9.8%, against 3.9% on placebo. On the higher dose, 64.5% of people lost at least 5% of their body weight; 35.1% of the placebo group did. Blood sugar moved too. Long-term blood sugar, measured as HbA1c, the three-month average that defines diabetes control, fell by up to 1.21 percentage points among people who stayed on treatment, and 29.5% of them reached readings in the normal, nondiabetic range. Four percent of the placebo group got there. People who kept taking the full dose for the whole stretch lost more than the overall average: up to 13.1% of their body weight.
The Stomach Paid the Toll
The drug’s costs landed mostly in the gut. Nausea, vomiting, diarrhea and constipation were common, affecting 73% to 78% of people on survodutide versus 39% on placebo, and most were mild or moderate. But 18% of those on the drug quit because of stomach side effects, against 1.2% on placebo. Most of those exits came during the early dose-escalation weeks, when the protocol marched everyone up on a fixed schedule. The company says its ongoing studies let doctors slow the climb for people who struggle.1 That’s a real limitation of these results, not a footnote. A medicine only works for the people who can stay on it.
A Crowded Field It Hasn’t Joined Yet
Several weight-loss drugs are already approved for people with type 2 diabetes, and a large analysis in The BMJ this year that pooled 262 randomized trials to rank the medications found tirzepatide at the top of the weight hierarchy, taking off about 15% of body weight in a year, with several others clustered near 10%.2 Survodutide’s numbers land in that middle cluster, though its trial enrolled only people with diabetes, who tend to be studied separately, so exact rankings are slippery. The same BMJ analysis carries a caution worth remembering here: scale numbers aren’t the whole story. Of 19 medications it compared, only injected semaglutide had evidence of helping people live longer, mainly because it’s the only one tested in trials long and large enough to show it. Survodutide now faces that same longer test. Its dedicated heart-outcomes trial is underway, with results expected before the year is out, and that reading will matter more than any weight percentage. Until regulators weigh in, this is a result to watch, not a prescription anyone can fill. What it signals for now is simpler: the menu of rigorously tested weight-loss medicines for people with diabetes keeps growing, and competition among them is being fought out in exactly the kind of long, blinded trials that produce trustworthy answers.
Key Takeaways
- Weekly survodutide led to a 9.8% average weight loss over 76 weeks in adults with type 2 diabetes, versus 3.9% with placebo, counting everyone who enrolled.
- Blood sugar improved alongside weight: nearly three in ten people who stayed on treatment reached normal-range HbA1c readings, compared with one in twenty-five on placebo.
- Stomach side effects drove 18% of participants off the drug, most during the fixed dose-escalation phase.
- The drug is investigational, the trial was company-funded, and approved alternatives with larger published weight reductions already exist.
References
- Wharton S, le Roux CW, Startseva E, et al. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. New England Journal of Medicine. 2026;NEJMoa2607219. link
- Nong K, Shi Q, Xie X, et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026;394:e372161. link